Table 3.
Percentages that drugs must deviate from default values (see Table 1) to result in treatment failure in naïve patients with no immunitya
| Drug | % Deviation for variable |
|||||
|---|---|---|---|---|---|---|
| Dose (mg/kg) | Parasite growth rate (a) (/day) | Elimination rate constant (k) (/day) | IC50 (mg/liter) | Vol of distribution (Vd) (liters/kg) | Maximal parasite-killing rate constant (V) (/day) | |
| Mefloquine | −95.6 | 169.6 | 598.1 | 2,122.2 | 2,082.7 | −56.5 |
| Mefloquine plus artesunate | −98.4 | 178.3 | 805.7 | 2,418.5 | 2,404.8 | −59.4 |
| Chloroquine | −66.5 | 100.0 | 332.9 | 160.0 | 160.0 | −40.3 |
| Chloroquine plus artesunate | −85.0 | 108.7 | 462.8 | 191.0 | 191.0 | −44.6 |
| Lumefantrine | −96.9 | 134.8 | 262.5 | 2,993.7 | 2,971.4 | −47.8 |
| Lumefantrine plus artemether | −99.0 | 169.6 | 837.5 | 5,868.0 | 5,852.0 | −56.5 |
| Lumefantrine plus artesunate | −98.4 | 152.2 | 462.5 | 4,275.0 | 4,171.4 | −50.7 |
| Piperaquine | −61.1 | 143.5 | 366.7 | 161.4 | 154.7 | −48.7 |
| Piperaquine plus DHA | −62.2 | 145.2 | 433.3 | 172.7 | 154.5 | −50.4 |
a
Positive values indicate that parameters must be increased for failure to occur, and negative values indicate that they must be decreased. Only partner drug PK/PD parameters are reported. The slope factor n did not influence treatment failure.